(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani - 2Find the Techniques for Powerful Review Propensities: Opening Your Scholarly Potential
- 3Ober Gabelhorn glacier reveals remains of man missing for over three decades
- 415 skywatching events you won't want to miss in 2026
- 5Planet-eating stars hint at Earth's ultimate fate
- China's 'Venice Of The East' Is A Historic Canal City Near Shanghai With Arched Bridges And Lantern-Lit Waterways
- What do scientists hope to learn from NASA's historic Artemis 2 moon flyby?
- Seven deaths possibly linked to malfunctioning glucose monitors
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- Hidden Island Cameras Capture Rare Tasmanian Species for the First Time Ever
- As juries turn against social media for harming kids, Big Tech's invincibility starts to show cracks
- Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship
- What to know about new CDC deputy director who has been critical of COVID vaccines
